PMID- 25388018
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141112
LR  - 20201001
IS  - 1523-3847 (Print)
IS  - 1523-3847 (Linking)
VI  - 16
IP  - 12
DP  - 2014 Dec
TI  - Use of intravenous immunoglobulin in critically ill patients.
PG  - 447
LID - 10.1007/s11908-014-0447-4 [doi]
AB  - Intravenous immunoglobulin (IVIG) has been suggested for the treatment of many 
      ailments due to its ability to modulate the immune system and to provide passive 
      immunity to commonly circulating pathogens. Its use as primary and adjunctive 
      therapy for the treatment of conditions affecting critically ill patients is an 
      attractive option, especially when alternative therapy does not exist. The body 
      of literature on the use of IVIG for the treatment of several serious conditions, 
      including sepsis, toxic shock syndrome, acute myocarditis, Stevens-Johnson 
      syndrome, toxic epidermal necrolysis, and H1N1 influenza, were reviewed. Despite 
      advances in treatment of these conditions since they were first described, there 
      remains a paucity of well-designed studies on the use of IVIG for their 
      treatment. Therefore, the use of IVIG for treatment of these conditions remains 
      controversial.
FAU - Donovan, Summer
AU  - Donovan S
AD  - Pediatric Infectious Diseases Fellow, Virginia Commonwealth University Health 
      System, VCU Sanger Hall 12-041, P.O. Box 980163, Richmond, VA, 23298-0163, USA, 
      sdonovan@mcvh-vcu.edu.
FAU - Bearman, Gonzalo M L
AU  - Bearman GM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Infect Dis Rep
JT  - Current infectious disease reports
JID - 100888983
EDAT- 2014/11/13 06:00
MHDA- 2014/11/13 06:01
CRDT- 2014/11/13 06:00
PHST- 2014/11/13 06:00 [entrez]
PHST- 2014/11/13 06:00 [pubmed]
PHST- 2014/11/13 06:01 [medline]
AID - 10.1007/s11908-014-0447-4 [doi]
PST - ppublish
SO  - Curr Infect Dis Rep. 2014 Dec;16(12):447. doi: 10.1007/s11908-014-0447-4.